The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

Autor:	Uwe Reuter, David W. Dodick, Gregor Broessner, Jan Klatt, Feng Zhang, Jo H. Bonner, Hernan Picard, Robert A. Lenz, Daniel D. Mikol, Yngve Hallstrom
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Adult Male medicine.medical_specialty Migraine Disorders Population efficacy Subgroup analysis Context (language use) Research Submissions Placebo Antibodies Monoclonal Humanized 03 medical and health sciences Young Adult 0302 clinical medicine Episodic migraine Double-Blind Method Internal medicine Medicine Humans In patient 030212 general & internal medicine Patient Reported Outcome Measures education Aged education.field_of_study business.industry responder thresholds Middle Aged medicine.disease Clinical trial Neurology Migraine erenumab episodic migraine Female Neurology (clinical) business STRIVE double‐blind treatment phase 030217 neurology & neurosurgery
Zdroj:	Headache
ISSN:	1526-4610 0017-8748
Popis:	OBJECTIVE To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6-month double-blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal clinical trial. METHODS Enrolled patients with episodic migraine (EM; ≥4 MMD and
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49e30b1c9495cfcf37668cbd16ba7a8c http://europepmc.org/articles/PMC7590156 Zobrazit plný text záznamu Plný text